NuVasive

NuVasive, Inc. engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. It offers a comprehensive portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NuVasive is a medical device company that creates minimally invasive surgical products and procedurally integrated spine solutions. Its minimally invasive, procedurally integrated surgical solutions are intended to produce repeatable and clinically proven results.

To stand tall against a competitive market, NuVasive depends on a strong spinal platform.

This Revolutionary Medical Device Company Goes to 11

SAN DIEGO, Aug. 9, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the appointment of Amy Belt Raimundo to the Company's Board of Directors, effective August 9, 2021. Ms.

Amy Belt Raimundo to Join NuVasive Board of Directors

SAN DIEGO, July 30, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that it received its latest U.S. Food and Drug Administration 510(k) clearance for the Pulse® platform, after receiving CE certification earlier this summer. In addition, the Company announced the commercial launch of Pulse which is now available for sale in targeted global regions.

NuVasive Receives Latest FDA 510(k) Clearance for Pulse Platform and Announces Commercial Launch

NuVasive (NUVA) reports strong segmental and geographical performance driving the top line in second-quarter 2021.

NuVasive (NUVA) Q2 Earnings Beat Estimates, Gross Margin Up

NuVasive, Inc. (NUVA) CEO Chris Barry on Q2 2021 Results - Earnings Call Transcript

NuVasive (NUVA) delivered earnings and revenue surprises of 39.54% and 3.03%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Beats Q2 Earnings and Revenue Estimates

SAN DIEGO, July 28, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2021. Second Quarter 2021 Highlights Net sales increased 44.8% to $294.8 million, or 43.3% on a constant currency basis; GAAP operating margin of 3.6%; Non-GAAP operating margin of 13.9%; and GAAP diluted earnings per share of $0.03; Non-GAAP diluted earnings per share of $0.60.

NuVasive Announces Second Quarter 2021 Financial Results

The Modulus ALIF 3D-printed porous titanium implant is the latest addition to NuVasive's (NUVA) AMS portfolio for anterior lumbar interbody fusion procedures.

NuVasive (NUVA) Launches Modulus ALIF for Anterior Spine Surgery

SAN DIEGO, July 22, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the commercial launch of Modulus® ALIF, a 3D-printed porous titanium implant for anterior lumbar interbody fusion (ALIF), in targeted global regions. "Modulus ALIF has been one of NuVasive's most successful clinical evaluations to date with continued surgeon adoption and overwhelmingly positive feedback.

NuVasive Launches Modulus ALIF 3D-Printed Porous Titanium Implant for Anterior Spine Surgery

NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NuVasive (NUVA) Earnings Expected to Grow: Should You Buy?

SAN DIEGO, July 14, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its second quarter 2021 earnings results on Wednesday, July 28, 2021, after the close of the market. NuVasive will hold a conference call on Wednesday, July 28, 2021, at 4:30 p.m.

NuVasive Announces Conference Call and Webcast of Second Quarter 2021 Results

We are upbeat about NuVasive's (NUVA) newly-introduced organizational and leadership structure for its global commercial operations as well as its product and services organization.

NuVasive (NUVA) International Sales Solid Despite COVID-19 Woes

The FDA informed healthcare providers of potential biocompatibility concerns with NuVasive Inc's (NASDAQ:NUVA) specialized orthopedics' Precice devices. Precice devices are implants for 18 years of age and older and are used to lengthen the limb, shorten or compress the limb, or transport segments of long bones.

FDA Flags Certain Biocompatibility Concerns For NuVasive's Orthopedics' Precice Devices

SAN DIEGO, June 30, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that the Pulse® platform received CE Mark approval for its latest design update and clinical evaluations are underway in multiple countries throughout Europe. "The latest CE Mark approval and clinical evaluations are key commercialization milestones for the Pulse platform and further our plan for an expanded global launch later this summer," said Massimo Calafiore, executive vice president, Global Business Units at NuVasive.

NuVasive Receives Latest CE Mark Approval for Pulse Platform and Starts Global Clinical Evaluations

NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock?

Why Is NuVasive (NUVA) Down 5.2% Since Last Earnings Report?

SAN DIEGO, May 19, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the appointment of Daniel J. Wolterman as independent chair of the NuVasive Board of Directors, effective immediately.

NuVasive Appoints Daniel J. Wolterman as Independent Board Chair

SAN DIEGO, May 10, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the appointment of Juliet C. Cunningham as the vice president of Investor Relations, effective immediately.

NuVasive Appoints Juliet C. Cunningham as Vice President of Investor Relations

NuVasive's (NUVA) first-quarter revenues improved year over year led by progress in U.S. procedural volumes and international business.

NuVasive (NUVA) Q1 Earnings Top Estimates, Gross Margin Up

NuVasive, Inc. (NUVA) CEO Chris Barry on Q1 2021 Results - Earnings Call Transcript

NuVasive (NUVA) delivered earnings and revenue surprises of 12.12% and 3.88%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Beats Q1 Earnings and Revenue Estimates

SAN DIEGO, May 5, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2021. First Quarter 2021 Highlights Net sales increased 4.4% to $271.2 million, or 3.1% on a constant currency basis; GAAP operating margin of 4.5%; Non-GAAP operating margin of 13.0%; and GAAP diluted loss per share of $0.15; Non-GAAP diluted earnings per share of $0.37.

NuVasive Announces First Quarter 2021 Financial Results

NuVasive (NUVA) has moved higher as of late, but there could definitely be trouble on the horizon for this company

NuVasive (NUVA) Enters Overbought Territory

SAN DIEGO, May 3, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that management will present at the following virtual investor conferences: Bank of America Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021 at 11:00 a.m. ET/ 8:00 a.m.

NuVasive to Present at Upcoming Investor Conferences

Analysts Estimate NuVasive (NUVA) to Report a Decline in Earnings: What to Look Out for

SAN DIEGO, April 19, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its first quarter 2021 earnings results on Wednesday, May 5, 2021, after the close of the market. NuVasive will hold a conference call on Wednesday, May 5, 2021, at 4:30 p.m.

News for NuVasive Stock (NUVA)